Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Baltics has shown significant growth in recent years.
Customer preferences: Customers in Baltics have become increasingly aware of the importance of early detection and treatment of cancer. This has led to a higher demand for oncology drugs and a shift towards more targeted therapies. Patients and healthcare professionals are looking for drugs that have fewer side effects and are more effective in treating specific types of cancer.
Trends in the market: The oncology drugs market in Baltics has been growing steadily due to the increasing prevalence of cancer and the aging population. The market is dominated by multinational pharmaceutical companies, but local players are also gaining traction. The market is expected to continue to grow due to the development of new drugs and the increasing demand for targeted therapies. However, the market is also becoming more competitive, with the entry of biosimilars and generics.
Local special circumstances: Baltics has a relatively small population, which means that the market for oncology drugs is also relatively small. However, the market is highly concentrated, with a few large hospitals and clinics accounting for a significant portion of the demand. This concentration has led to a high level of competition among drug manufacturers and a focus on developing drugs that are more effective and have fewer side effects.
Underlying macroeconomic factors: Baltics has a relatively stable economy, with a growing healthcare sector. The government has been investing in healthcare infrastructure and increasing access to healthcare services. However, there are also challenges, such as an aging population and a shortage of healthcare professionals. These factors are expected to drive demand for oncology drugs in the region. Additionally, the region's membership in the European Union has led to increased access to new drugs and technologies, which is expected to further drive growth in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
